Biotie Therapies - Major shareholder announcements

Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 12 January 2011 at 2.30 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of the
notification regarding changes in holdings in accordance with Chapter 2, Section
9 of the Finnish Securities Markets Act, described below.

The notification received by the Company concern the changes in holdings in the
Company of Versant Ventures III LLC (through Versant Venture Capital III LP and
Versant Side Fund III LP).

The mentioned parties are parties to a Combination Agreement entered into on 10
January 2011 among the Company, Synosia Therapeutics Holding AG ("Synosia") as
well as Synosia's shareholders and warrant holders, described in more detail in
a stock exchange release issued on 11 January 2011, under which agreement the
Company will issue 161,448,371 shares to the shareholders and warrant holders of
Synosia in an acquisition of the entire issued share capital and outstanding
warrants of Synosia (the "Transaction") upon completion of the Transaction. In
connection with the Transaction, the Company will issue 14,912,155 to Synosia to
be held in treasury and used to satisfy future potential exercise of Synosia's
options. The completion of the Transaction is subject to the necessary
resolutions passed by the Company's shareholders at the Extraordinary General
Meeting of Shareholders to be held on 1 February 2011, the approval by the
Finnish Financial Supervisory Authority of the prospectus in relation to the
listing of the issued shares as well as certain other conditions.

According to the notification received by the Company, none of the notifying
parties currently hold shares or votes in the Company and the resulting holdings
of shares and votes in the Company of the notifying parties after possible
completion of the Transaction and the registration of the shares to be issued
with the Finnish Trade Register would be as follows:

Name              Number of shares  Voting rights     Share of      Share of
                  to be received    shares to be      share capital voting
                  subject to        received subject  (%)           rights (%)
                  completion of     to completion of
                  Transaction       Transaction

Versant Venture   34,067,104        34,067,104        9.67          10.56
Capital III LP
(controlled by
Versant Ventures
III LLC)

Versant Side Fund 201,237           201,237           0.06          0.06
III LP
(controlled by
Versant Ventures
III LLC)

Versant Ventures  34,268,341        34,268,341        9.73          10.62
III LLC (through
Versant Venture
Capital III LP
and Versant Side
Fund III LP) in
total



The number of voting rights and percentages presented above are calculated based
on number of shares and voting rights to be obtained upon completion of the
Transaction taking into account the treasury shares held by the Company on the
date of the notification.

On the date hereof, the registered number of shares in Biotie Therapies Corp. is
176,003,931. Of these shares 14,747,084 are held by the Company and the number
of outstanding shares and voting rights attached to the shares amounts thus to
161,256,847. Subject to the completion of the Transaction and subsequent to the
subscription and registration of the new shares to be issued in connection with
the Transaction, the aggregate number of Biotie shares will be 352,364,457. Of
these shares, 29,659,239 will be held by the Company or its group companies.



Turku, 12 January 2011



Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1479197]